Loading…
A resolution designating the month of May 2016 as "Cystic Fibrosis Awareness Month".
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 642 other SRES bills in the 114th — cohort avg 10d
(This measure has not been amended since it was introduced. The summary of that version is repeated here.) Designates May 2016 as Cystic Fibrosis Awareness Month. (Cystic fibrosis is an inherited disease that causes persistent lung infections and limits the ability to breathe over time.) Congratulates the individuals who care for patients with cystic fibrosis for their dedication. Recognizes that the care delivery system for cystic fibrosis can be a model for care coordination. Acknowledges the investments and scientific achievements that have improved the lives of individuals with cystic fibrosis. Urges researchers, developers, patients, and providers to work together to find a cure for this deadly disease.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2016 · fourth_quarter · Health Issues
PL 111-148 - The Patient Protection and Affordable Care Act, implementation FDA User Fee Reauthorizations, drug development policies, accelerated approval PL 112-144 - The Food and Drug Administration Safety and Innovation Act, implementation H.R. 3204 - The Drug Quality and Security Act, implementation H.R. 6 - 21st Century Cures Innovation For Healthier Americans S. 2030 - Advancing Targeted Therapies for Rare Diseases Act S. Res. 476 - Cystic Fibrosis Awareness H.R. 34 - 21st Century Cures Act ***, no specific bill, Raising Awareness of Cystic Fibrosis ***, no specific bill, appropriations for the Department of Health and Human Services, PDUFA, Sunshine, Orphan drugs, 340B, Innovation S. 273 - Advancing Precision Medicine Act of 2016
Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S3227; text as passed Senate: CR S3175-3176)
Passed/agreed to in Senate: Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent.(consideration: CR S3227; text as passed Senate: CR S3175-3176)
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · third_quarter · Health Issues
PL 111-148 - The Patient Protection and Affordable Care Act, implementation FDA User Fee Reauthorizations, drug development policies, accelerated approval PL 112-144 - The Food and Drug Administration Safety and Innovation Act, implementation H.R. 3204 - The Drug Quality and Security Act, implementation H.R. 6 - 21st Century Cures Innovation For Healthier Americans S. 2030 - Advancing Targeted Therapies for Rare Diseases Act S. Res. 476 - Cystic Fibrosis Awareness ***, no specific bill, Raising Awareness of Cystic Fibrosis ***, no specific bill, appropriations for the Department of Health and Human Services, PDUFA, Sunshine, Orphan drugs, 340B, Innovation S. 273 - Advancing Precision Medicine Act of 2016
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · second_quarter · Health Issues
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016. S. Res. 476, Designating the month of May 2016 as "Cystic Fibrosis Awareness Month."
Client expense: $440,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · second_quarter · Health Issues
PL 111-148 - The Patient Protection and Affordable Care Act, implementation FDA User Fee Reauthorizations, drug development policies, accelerated approval PL 112-144 - The Food and Drug Administration Safety and Innovation Act, implementation H.R. 3204 - The Drug Quality and Security Act, implementation H.R. 6 - 21st Century Cures Innovation For Healthier Americans S. 2030 - Advancing Targeted Therapies for Rare Diseases Act S. Res. 476 - Cystic Fibrosis Awareness ***, no specific bill, Raising Awareness of Cystic Fibrosis ***, no specific bill, appropriations for the Department of Health and Human Services, PDUFA, Sunshine, Orphan drugs, 340B, Innovation S. 273 - Advancing Precision Medicine Act of 2016
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE